Anti-inflammatory drugs are commonly spread and used to treat pain, arthrosis, asthma or psoriasis. Our laboratory has developed a new molecule against these diseases with some interesting results.

 

Different classes of anti-inflammatory drugs are known to inhibit cycloxygenase  enzymes (COXs). However inhibition of the COX by common non-steroidal anti-inflammatory drugs is also known to cause side effects such as gastric ulceration due to lack of selectivity between COX-1 and COX-2. Moreover, some of these drugs, containing a nitrophenyl nucleus, present a high risk of toxicity.

The laboratory has discovered new pyridinic sulfonamide derivatives developed for the treatment of inflammation (arthrosis, rheumatoid arthritis) and pain. 

 

 

·      Advantages

This invention is based on the isosteric replacement of the nitrobenzenic nucleus of N-(nitrophenyl)alkanesulfonamide NSAIDs by a pyridine nucleus. It  results in:

- a strong anti-inflammatory activity in vivo in animal models ;

- a beneficial profile as COX-2 preferential or COX-2 selective inhibitors;

- expected poor side effects and toxicity.

 

·      Potential Applications

 

The pyridinic sulfonamide derivatives can enter in pharmaceutical

composition as active therapeutic substances in the treatment of

diseases in which they can play a role as COX-2

preferential/selective inhibitors (arthrosis, cancer, pain…). 

 

 

Early Stage

 

Granted : US 7226936, RU 2309148, AU 202337116, EP 1432684

Pending : WO 03/029217 – US 2007-0173534A1, CA 2460144, JP 2005-504125

 

 

The laboratory is looking for out-licensing opportunity for the compounds and their method of synthesis.

 

·      Development stage

Different news compounds have been identified and their synthesis is set up. In vivo studies in animals show promising results.

 

 

 

US7226936,RU2309148,AU202337116,EP1432684,WO2003029217,US2007173534,CA 2460144,JP 2005504125